Oncology Data Advisor® · Exciting New Directions for Oncology Data Advisor: Live From ASCO 2023 With Dr.Thomas Abrams At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Thomas Abrams, Editor in Chief of Oncology Data Advisor, previewed some of the latest updates on Oncology Data Advisor and the new di...
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Thomas Abrams, Editor in Chief of Oncology Data Advisor, previewed some of the latest updates on Oncology Data Advisor and the new directions that will be taken in 2023, including new ways of partnering with patients to strengthen the patient voice and ultimately improve quality of care.
Oncology Data Advisor® · Understanding and Improving Quality of Life for Cancer Patients Through Nursing Research Following the recent 48th Oncology Nursing Society (ONS), Terri Armstrong, the Senior Investigator and Deputy Chief of the Neuro-Oncology Branch at the National Institutes of Health (NIH), sat down with Oncology Data Advisor®...
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® had the privilege of interviewing many distinguished physician, nurse, pharmacist, pathologist, and patient advocate speakers about their work and research. These exclusive video and podcast playlists feature more than 30 conversations on a range of topics in oncology treatment and patient care, including the following:
Oncology Data Advisor® · Developing Telegenetic Cancer Risk Assessment for Black Individuals With Darya Kizub, MD
At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Darya Kizub, Hematology-Oncology Fellow at MD Anderson Cancer Center, presented her team's research regarding a novel initiative for recruiting Black individuals to be screened for hereditary cancer genetic testing eligibility. Prior to presenting, she sat down with Oncology Data Advisor to share more about the need to provide cancer genetic testing for Black individuals and the ways that she and her team have partnered with the community to enact this change.
Oncology Data Advisor® · Expanding Global Health Education Through Video and Social Media With Yan Leyfman, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Dr. Yan Leyfman, a physician at Mount Sinai Hospital and Director and Host of MedNews Week. Dr. Leyfman expl...
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Dr. Yan Leyfman, a physician at Mount Sinai Hospital and Director and Host of MedNews Week. Dr. Leyfman explains the origin and reach of MedNews Week and how it strives to combat health care information, champion patient advocacy, and expand global health education through its video and social media platforms.
In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investigator Track Resident, his plans for applying to an oncology fellowship, advice for navigating the experience, tips for acquiring o...
In 2006, after being diagnosed with breast cancer at the age of 32, Maimah Karmo decided to dedicate herself to empowering women with breast cancer to serve as advocates for themselves, resulting in the creation of Tigerlily Foundation. In this interview, Ms. Karmo shares more of her story and her passion for amplifying the patient's voice, increas...
Oncology Data Advisor® · Renal Cell Carcinoma Research and Shared Decision Making With Bradley McGregor, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Bradley McGregor, MD, Director of Clinical Research for the Lank Center of Genitourinary Oncology at th...
Oncology Data Advisor® · Exploring Primary Overall Survival Results of Axicabtagene Ciloleucel in ZUMA-7: Jason Westin, MD
At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jason Westin, Director of Lymphoma Clinical Research at MD Anderson Cancer Center, presented the primary overall survival analysis of the phase 3 ZUMA-7 trial investigating axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomas. In this interview, he shares more with Oncology Data Advisor regarding the efficacy, safety, and future directions of this promising agent.
Oncology Data Advisor® · Medical Cannabis Educational Training for Oncology Fellows With Deepa Rangacharia, MD
At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Dr. Deepa Rangachari, Director of Hematology/Oncology Graduate Medical Education at Beth Israel Deaconess Medical Center, to learn more about her presentation on her team's development of a novel curriculum to train Hematology/Oncology Fellows in the use of medical cannabis for their patients.
Oncology Data Advisor® · Social Media’s Effect on Informed Decision Making in Cancer Treatment Welcome to Oncology Data Advisor®, a digital resource for the multidisciplinary cancer team. In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill Universit...
In this Oncology Data Advisor® Fellows Forum interview, Richa Thakur, MD, Hematology/Oncology Fellow at Northwell Health, speaks with Nida Khan, MD, a third-year Internal Medicine Resident who is beginning a joint Medical Oncology and Palliative Care Fellowship this July. Dr. Khan discusses the unique opportunities provided by this new type of fellowship, her passions for palliative care and global health, and advice for navigating the fellowship application process to find your niche in the program that is the best fit for you.
Oncology Data Advisor® · Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD
In May 2023, the FDA granted approval to epcoritamab, a CD3-redirecting, CD20-targeting bispecific antibody, for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. Following the approval, Oncology Data Advisor® spoke with Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Institute and one of the investigators of the EPCORE NHL-1 trial, on which the approval was based, to learn more about the efficacy and safety of epcoritamab and its burgeoning role in the treatment of relapsed/refractory DLBCL.
Oncology Data Advisor® · HemePath Hub, a Unique Learning Opportunity: Dr. Aamir Ehsan and Dr. Bridget Herschap
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Dr. Aamir Ehsan and Dr. Bridget Herschap from CorePath Laboratories. Dr. Ehsan and Dr. Herschap describe the HemePath Hub, a unique learning opportunity offered by CorePath in which pathologists, residents, and fellows can receive continuing educational training in the cutting-edge technology, business innovation, and specialized skills encompassing all aspects of pathology for hematologic cancers.
Oncology Data Advisor® · Pickles Group: Supporting Kids Impacted by Parental Cancer With Cassy Horton
In this interview from the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor speaks with Cassy Horton, Executive Director of Pickles Group, a nonprofit organization supporting the social and emotional wellbeing of children whose parents have cancer.
In May 2023, the FDA granted approval to epcoritamab, a CD3-redirecting, CD20-targeting bispecific antibody, for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. Following the approval, Oncology Data Advisor® spoke with Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Institute and one of the investigators of the EPCORE NHL-1 trial, on which the approval was based, to learn more about the efficacy and safety of epcoritamab and its burgeoning role in the treatment of relapsed/refractory DLBCL.
Oncology Data Advisor® · Social Determinants of Health and Genetic Testing in Triple-Negative Breast Cancer: Barb Kunz, LCGC
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor® sat down with Barb Kunz, a Senior Genetic Counselor at the US Oncology Network, to talk about her research on rates of germline testing for BRCA1 and BRCA2 mutations in patients with triple-negative breast cancers and her presentation on the impacts of social determinants of health on genetic testing.
Oncology Data Advisor® · Getting to the Heart of Cardio-Oncology With Jessica Coviello, DNP, RN, ANP-BC At the 48th Annual Oncology Nursing Society (ONS) Congress, Oncology Data Advisor® spoke with Jessica Coviello, Associate Dean of Faculty Development at Cizik School of Nursing at the University of Texas, Houston. Dr. Coviello shares t...